Recent advances in blood cancer treatments are offering patients safer options and longer-lasting remissions. Studies highlight the potential of CAR T-cell therapy in multiple myeloma, a gentler ...

Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...

Pfizer said on Wednesday its drug Elrexfio met the main goal in a ​late-stage trial that tested the blood cancer ‌treatment ...

US pharma giant Pfizer has announced positive topline results from the Phase III MagnetisMM-5 study of Elrexfio (elranatamab) ...

Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...

Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma: New York Thursday, April 30, 2 ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...

Phase 3 MagnetisMM-5 trial data in multiple myeloma highlight progression-free survival gains and key safety considerations ...

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...